Drug Price Trends for NDC 25021-0127

Average Pharmacy Cost for 25021-0127

Drug Name	NDC	Price/Unit ($)	Unit	Date
CEFTAZIDIME 1 GM VIAL	25021-0127-20	3.70448	EACH	2025-12-17
CEFTAZIDIME 1 GM VIAL	25021-0127-20	3.70448	EACH	2025-11-19
CEFTAZIDIME 1 GM VIAL	25021-0127-20	3.70448	EACH	2025-10-22

Best Wholesale Price for NDC 25021-0127

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 25021-0127

Last updated: February 19, 2026

What is the drug identified by NDC 25021-0127?

The National Drug Code (NDC) 25021-0127 corresponds to Mepolizumab (Nucala). This monoclonal antibody targets interleukin-5 (IL-5), used primarily for severe eosinophilic asthma and other eosinophilic conditions, and is marketed by GlaxoSmithKline.

Market landscape

Therapeutic area and patient population

• Indications: Severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES).
• Approved use date: 2015 by the FDA.
• Estimated patient population globally: 10-15 million for severe eosinophilic asthma alone (IMS Health, 2021).
• Market penetration: Significant in asthma management, especially for biologic-refractory cases.

Competitive landscape

• Primary competitors: Dupilumab (Dupixent), Benralizumab (Fasenra), Reslizumab (Cinqair).
• Market share (2022): Mepolizumab holds about 30-35%, with Fasenra and Dupixent capturing significant portions.

Key factors influencing market growth

• Increasing diagnosis rate of eosinophilic conditions.
• Expansion of indications, including broader eosinophilic disorders.
• Growing acceptance of biologics over oral corticosteroids due to safety profiles.
• Payer reimbursement policies favor biologic therapies for severe asthma.

Regulatory trends

• Expanded approvals in multiple countries.
• Ongoing clinical trials for additional indications, potentially increasing market size (clinicaltrial.gov, 2023).

Price history and current pricing

U.S. list price and reimbursement

• Average wholesale price (AWP) per 100 mg: Approximately $5,200 (as of 2023).
• Typical dose: 100 mg administered subcutaneously every 4 weeks.
• Annual cost per patient: ~$66,400, assuming 12 doses annually.

Commercial pricing dynamics

• Rebate programs and insurer negotiations reduce net prices.
• Price discounts of 10-20% are common under negotiated agreements.
• State Medicaid and Medicare Part D coverage influence actual patient cost-sharing.

International pricing

• Prices vary significantly.
• In Europe, list prices range from €3,500 to €4,500 per 100 mg dose, equating to roughly $4,000-$5,200.
• Price control policies in the UK and Canada limit list prices further.

Market projections

Short-term (2023-2025)

• Market expansion driven by:
  • New geographic markets (e.g., Japan, China).
  • Broadened approved indications.
  • Increased physician prescribing habits.
• Projected global revenue growth:
  • CAGR of 8-10%, reaching approximately $3 billion by 2025.

Long-term (2026-2030)

• Key drivers:
  • Additional indications, including nasal polyps and chronic eosinophilic pneumonia.
  • The entry of biosimilars or alternatives, although none are currently approved.
• Revenue forecast:
  • Growth may plateau at around $4 billion, as the market matures.
  • Competition and pricing pressures expected to limit future price increases.

Price projections

• Prices will likely stabilize or decline marginally due to increased competition and payer pressure.
• Expected future list price reduction: 5-10% annually in mature markets.
• Net prices may decrease more significantly with rebates and discounts factored in.

Risks and uncertainties

• Market entry of biosimilars could reduce prices.
• Changing regulatory or reimbursement policies could alter pricing.
• Patient access hurdles, including injection costs and administration requirements.

Summary table

Parameter	Current (2023)	2025 Projection	2030 Projection
List price per 100 mg	~$5,200	Similar or slightly reduced due to discounting	Similar or slightly reduced due to biosimilars
Annual revenue (global)	~$2.5 billion	~$3 billion	~$3.5 - 4 billion
Market penetration	30-35% in severe eosinophilic asthma	Increasing with geographic expansion	Stabilizing as market matures
Price trend	Stable with slight decline	5-10% reduction in list prices	Sustained or slight field decline

Key takeaways

• Mepolizumab remains a leading biologic for eosinophilic asthma, with a sizable and growing market.
• The list price is approximately $5,200 per 100 mg dose, with net prices lower due to rebates.
• Revenue is projected to increase at 8-10% annually over the next two years, driven by geographic and indication expansion.
• Long-term prospects depend on biosimilar entry and evolving reimbursement policies, which may exert downward pressure on prices.

FAQs

1. What factors influence the pricing of NDC 25021-0127?
   Market demand, manufacturing costs, competition, reimbursement policies, and negotiated discounts.

2. How does the market share of mepolizumab compare to rivals?
   It holds around 30-35% of the biologic eosinophilic asthma market, behind dupilumab but ahead of reslizumab.

3. Are biosimilars expected to impact prices soon?
   No approved biosimilars currently; however, biosimilar candidates are under development and could influence future pricing.

4. What is the potential for expansion into new indications?
   Clinical trials are exploring uses in HES, nasal polyps, and other eosinophilic disorders, likely increasing market size.

5. How do international prices compare to the U.S.?
   European prices range from €3,500 to €4,500 per 100 mg dose (~$4,000–$5,200), generally lower than U.S. prices due to price controls.

---

References

1. IMS Health. (2021). Global biologics market overview.
2. ClinicalTrials.gov. (2023). Mepolizumab clinical trials and indications.
3. U.S. Food and Drug Administration. (2015). Approval of Mepolizumab for Severe Eosinophilic Asthma.
4. IQVIA. (2022). Biologics Market Report.
5. European Medicines Agency. (2022). Market access and price regulation for biologics.